Meta‐Analysis of the Risk of Immune‐Related Adverse Events With Anticytotoxic T‐Lymphocyte‐Associated Antigen 4 and Antiprogrammed Death 1 Therapies

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|103|2|318-331

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.103, Iss.2, 2018-02, pp. : 318-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene Polymorphisms in Japanese Children with Infection-Associated Hemophagocytic Lymphohistiocytosis

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-03 ,pp. : 186-190

Karger

Access to resources Recommend Favorite

Reply to ‘Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials’: reply from the authors

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1766-1767

John Wiley & Sons Inc

Access to resources Recommend Favorite

An IPDMA on factors associated with ADEs in surgical and non‐surgical inpatients

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 4, 2015-04 ,pp. : 548-557

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-04 ,pp. : 296-300

Karger

Access to resources Recommend Favorite

The MDM2 309 T/G Polymorphism is Associated with Head and Neck Cancer Risk Especially in Nasopharyngeal Cancer: A Meta-Analysis

By  

Oncology Research and Treatment, Vol. 35, Iss. 11, 2012-10 ,pp. : 666-670

Karger

Access to resources Recommend Favorite